Patient case (clinical description): A 41-year-old woman comes to the dermatology clinic complaining of facial redness, especially on her forehead and cheeks. She noticed that the redness gets worse in the summer and after sun exposure. She is otherwise healthy. On physical examination, she has multiple papules and pustules present on her forehead, cheeks, and nose on a background of erythema and telangiectasias. There are no other lesions or nodules. The patient is married and has 2 children who are 5 and 9 years old. She has IUD and doesn't wish to have more kids. She does not smoke or drink alcohol. Her vital signs are normal, and BMI is 21.

Patient's own account: I'm 41, married with 2 lovely kids who are 5 and 9 years old. I have an IUD and I don't want to have more kids. I don't smoke or drink alcohol. I had to go to the dermatology clinic because I had terrible redness on my face, especially on my forehead and cheeks. It got worse in the summer and after being under the sun. I'm usually healthy. They conducted a physical exam and they found several lesions and pustules on my forehead, cheeks and nose and they also found some signs of erythema and telangiectasia. My vitals were normal, and my BMI is 21.

Clinical trial: Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias

Eligibility criteria:
Inclusion Criteria:

          -  Patients with moderate to severe facial telangiectasias referred to laser or
             IPL-treatment. Severity and distribution of telangiectasias must be symmetrical
             between left and right side of the face in the individual patient

          -  Telangiectasias may be observed in connection with rosacea, but rosacea must not
             demonstrate clinical active inflammation or acne

          -  18-65 years of age

          -  Fitzpatrick skin type I-III

          -  Fertile women must document non-reactive urine pregnancy test at the day of inclusion

          -  During the study, fertile women must be using effective birth control. Effective
             contraception is defined as follows:

               -  Injectable, implantable or orally taken hormones;

               -  Intrauterine device;

               -  Trans-abdominal surgical sterilization;

               -  Sterilization implant device;

               -  Surgical sterilization of male partner;

               -  Complete abstinence from sexual intercourse for two weeks before exposure to
                  study medication and throughout the clinical study

          -  Verbal and written consent to participate in the study

          -  Documentation of medicine status

        Exclusion Criteria:

          -  Clinical active dermatological disease in the face

          -  Wounds, dermatitis, tattoos or scars in treatment area

          -  Allergies to ingredients in Mirvaso

          -  Current treatment with monoamine oxidase inhibitors, tricyclic or tetracyclic
             antidepressants which interacts with the noradrenergic transmission

          -  Current treatment with other systemic adrenergic receptor agonists or antagonists

          -  Patients with known liver or renal disease

          -  UV-exposure (solarium or sunbathing) or other treatment within the last month that
             enhances skin pigmentation

          -  Use of other topical agents that may interact with treatment

          -  Local or systemic treatment with photosensitizing drugs

          -  Pregnancy and breastfeeding women

          -  Current participation in other clinical trials

          -  Patients that are considered incapable of complying with the protocol, i.e. patients
             suffering from dementia, alcoholism or psychiatric conditions
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 65 Years

Eligibility (NLI label): Entailment